- Home
- PHUN vs ENTX Comparison
PHUN vs ENTX Comparison
Compare PHUN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | ENTX |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 142.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PHUN | ENTX |
|---|---|---|
| Price | $2.05 | $2.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.25 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 152.8K | 76.2K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,357,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $1.83 | $1.50 |
| 52 Week High | $6.29 | $3.22 |
Technical Indicators
Market Signals| Indicator | PHUN | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 40.14 |
| Support Level | $2.01 | $2.07 |
| Resistance Level | $2.16 | $2.27 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 41.38 | 15.44 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.